Tonix Pharma’s TNX-102 SL Advances in FDA Process

Tonix Pharma ( (TNXP) ) has shared an update.

On March 24, 2025, Tonix Pharmaceuticals announced that the FDA will not require an Advisory Committee meeting for the New Drug Application of TNX-102 SL, a product candidate for fibromyalgia management. This development could streamline the approval process, potentially accelerating the product’s market entry and impacting the company’s operations and market positioning positively.

More about Tonix Pharma

Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on developing innovative therapies for central nervous system disorders, immunology, and infectious diseases. Their primary product candidates include TNX-102 SL for fibromyalgia management.

YTD Price Performance: -30.17%

Average Trading Volume: 1,541,769

Technical Sentiment Signal: Buy

Current Market Cap: $148.2M

See more data about TNXP stock on TipRanks’ Stock Analysis page.